Chagas disease future or investigational therapies

Chagas disease Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Chagas disease from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Criteria
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Chagas disease future or investigational therapies On the Web
Most recent articles
cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Chagas disease future or investigational therapies All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Chagas disease future or investigational therapies
CDC on Chagas disease future or investigational therapies
Chagas disease future or investigational therapies in the news
Blogs on Chagas disease future or investigational therapies
Directions to Hospitals Treating Chagas disease
Risk calculators and risk factors for Chagas disease future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Yazan Daaboul, M.D.

Overview

Although novel investigational drugs are being studied for chronic Chagas disease, to date no new pharmacologic therapy has proven to be effective compared with the current standard of care (benznidazole therapy)

Investigational Therapies

• Clinical trials that evaluate the efficacy of novel investigational therapies for chronic Chagas disease are scarce, primarily because it has been difficult for researchers to define efficacy endpoint in clinical trials in the past.

• The introduction of PCR results for the evaluation of drug success has been useful for the study of novel investigational drugs
• The following investigational drugs have been studied. Although the drugs were associated with high rates of negative PCR successful results immediately post-treatment, long-term follow-up demonstrated that the majority of patients who received those drugs relasped with positive PCR results.

• Posaconazole - Patients in the posaconazole arm had a significantly higher rate of positive PCR during 12-month follow-up compared with the benznidazole arm.

• Ravuconazole - Patients in the ravuconazole arm had a significantly higher rate of positive PCR during 12-month follow-up compared with the benznidazole arm.